Skip to content
Find a Provider
Rachael B. Turner, M.D., Ph.D.

Rachael B. Turner, M.D., Ph.D.

Gynecologic Cancer , Obstetrics & Gynecology , Hematology & Oncology , Cancer

4.8 out of 5 stars
275 Ratings
17 Comments
UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Appointment (585) 442-8020
Fax (585) 442-8039

Locations

Gynecologic Oncology - Rochester

Lattimore Medical Center
125 Lattimore Road, West Entrance, Suite 258
Rochester, NY 14620

(585) 442-8020 Get Directions
Highland Hospital - Gynecologic Oncology - Rochester

Highland Hospital
1000 South Avenue
Rochester, NY 14620

(585) 442-8020 Get Directions

About Me

Dr. Rachael Turner received her medical degree and her PhD from the University at Buffalo School of Medicine and Biomedical Sciences in 2013. Dr. Turner then completed her Internal Medicine Residency and Medical Oncology Fellowship at the University of Rochester Medical Center in 2015 and 2018, resp...
Dr. Rachael Turner received her medical degree and her PhD from the University at Buffalo School of Medicine and Biomedical Sciences in 2013. Dr. Turner then completed her Internal Medicine Residency and Medical Oncology Fellowship at the University of Rochester Medical Center in 2015 and 2018, respectively. She is currently pursuing a Research Fellowship at the University of Rochester Medical Center. Dr. Turner is certified by the American Board of Internal Medicine.

Dr. Turner's special interests are women's cancers, including fallopian, ovarian, uterine and cervical. She is also interested in immune therapies for cancer. Dr. Turner is committed to providing personalized cancer care with compassion and dedication.

During her free time, Dr. Turner enjoys spending time with her husband and sons, running and hiking.

Certified Specialties

Internal Medicine - American Board of Internal Medicine

Medical Oncology - American Board of Internal Medicine

Faculty Appointments

Assistant Professor - Department of Medicine, Hematology/Oncology (SMD)

Assistant Professor - Department of Obstetrics and Gynecology (SMD) - Joint

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, University of Rochester Medical Center. 2015 - 2018

Residency, Internal Medicine, University of Rochester Medical Center. 2014 - 2015

Internship, Internal Medicine, University of Rochester Medical Center. 2013 - 2014

Education

MD | SUNY at Buffalo-School of Medicine & Biomedical Sciences (USA). 2013

Awards

Internal Medicine Department Faculty Pilot Award. 2020 - 2021

Technology Development Fund Grant. 2019 - 2020

W.G Stuber Research Award. 2019 - 2020

Wilmot Fellowship Award. 2018

Conquer Cancer Foundation/Women who Conquer Cancer- Young Investigator Award. 2018

Best Overall Poster Presentation for HE4 in Ovarian Cancer Immune Suppression Poster Presentation. 2017

Harold Brody Award for Translational Research. 2011

Honorable Mention for poster presentation on Chronic Chemoimmunotherapy etc... 2010

Breast Cancer Pre-doctoral Traineeship Award. 2009 - 2011

Guy A. Bailey Outstanding Senior Award. 2005

Phi Beta Kappa National Honor Society. 2005

Tri-Beta Honor Society. 2004

Publications

Journal Articles

HE4 Overexpression by ovarian cancer promotes a suppressive tumor immune microenvironment and enhanced tumor and macrophage PD-L1 expression. Published online April 26,2021:

Rowswell-Turner R; Singh R; Urh A; Yano N; Kim K; Khazan K; Pandita, R; Sivagnanalingam U; Hovanesian V; James N; Ribeiro J; Kadambi S; Linehan D; Moore R.

J Immunol. 2021; .

Development of Potent Forchlorfenurone Analogs and Their Cytotoxic Effect in Cancer Cell Lines.

Kim KK; Singh RK; Khazan N; Kodza A; Singh NA; Jones A; Sivagnanalingam U; Towner M; Itamochi H; Turner, R; Moore RG.

Sci Rep. 2020; 10(1): 3241.

Role of trypsin and protease-active receptor-2 in ovarian cancer.

Kim KK; Turner R; Khazan N; Kodza A; Jones A; Singh RK; Moore RG.

PLOS One. 2020; 15(5): e0232253.

The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes.

James NE; Emerson JB; Borstadt; Beffa L; Liver MT; Hovanesian V; Urh A; Singh RK; Rowswell-Turner R; DiSilvestro PA; Ou J; Moore RG; Ribeiro JR.

Sci Rep. 2020; 10(1): 8558.

Novel small molecule MEK inhibitor URML-3881 enhances cisplatin sensitivity in clear cell ovarian cancer.

Rowswell-Turner R; Rutishauser J; Kim KK.

Translat Oncol. 2019; 12(7): 914-924.

Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6.

James NE, Oliver MT, Ribeiro JR, Cantillo E, Rowswell-Turner RB, Kim KK, Chichester CO, DiSilvestro PA, Moore RG, Singh RK, Yano N, Zhao TC

Frontiers in pharmacology.. 2019 10 :216. Epub 03/19/2019.

HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells. Clin Exp Immunol. Epub ahead of print.

James, N.E.; Cantillo, E. ;Oliver, M.T.; Rowswell-Turner, R.B.

2018; .

Novel small molecule MEK inhibitor URML-3881 enhances cisplatin sensitivity in clear cell ovarian cancer. Manuscript submitted for publication.

Rowswell-Turner R, Rutishauser J, Kim KK et al.

2018; .

Treatment of chronic lymphocytic leukemia in older adults.

Rowswell-Turner, R.B; and Barr, P.

J Geriatric Oncology. 2017; 8(5): 315-319.

Chemoimmunotherapy as long-term maintenance therapy for cancer.

Egilmez, N.K.; Harden, J.L.; Rowswell-Turner, R.B.

Onco Immunology. 2012; 1(4): 1-3.

2012. Magnetic resonance spectroscopy of adult thalamic glioblastoma multiforme. N Am J Med Sci. 5(1):51-54.

Li, P.; Liu, Y.; Rowswell-Turner,R. B.; Esfahani, F.

2012; .

Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation.

Rowswell-Turner, R.B.; Harden, J.L.; Nair,R.E;, Gu,T.; Kilinc,M.O.; Egilmez, N.K.

J Immunology. 2011; 187(8): 4109-18.

Dichotomous effects of IFN-y on dendritic cell function determine the extent of IL-12-driven antitumor T-cell immunity.

Harden, J.L.; Gu, T.; Kilinc, M.O.; Roswell-Turner, R.B.; Virtuoso, L.P.; Egilmez, N.K.

J Immunology. 2011; 187(1): 126-32.

Central Role of IFNgamma-indoleamine 2,3- dioxygenase axis in regulation of interleukin- 12- mediated antitumor immunity.

Gu, T.; Roswell-Turner, R.B.; Kilinc, M.O.; Egilmez, N.K.

Cancer Res. 2010; 70(1): 129-38.

Activated CD8+ T-effector/memory cells eliminated CD4+CD25+Foxp3+ T- suppressor cells from tumors via FasL mediated apoptosis

Kilinc, M.O.; Roswell-Turner, R.B.; Gu, T.; Virtuoso, L.P.; Egilmez, N.K.

J Immunology. 2009; 183(12): 7656-60.

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

Care provider's discussion of any proposed treatment (options, risks, benefits, etc.)

4.8 stars

Likelihood of recommending this care provider to others

4.7 stars

Explanations the care provider gave you about your problem or condition

4.8 stars

Care provider's efforts to include you in decisions about your care

4.8 stars

Concern the care provider showed for your questions or worries

4.8 stars

Patient Comments

5.0 stars

The Doctor took her time and explained everything very fully taking time to make sure I understood and addressed any concerns I expressed. Very good experience.

Dec 01, 2024

2.2 stars

Oncologist is not open and forth coming about treatment or the cancer. If I ask the right question, I get some info, but she does not volunteer

Sep 02, 2024

5.0 stars

Dr Turner patient and thorough

Jan 16, 2024

5.0 stars

Dr Turner always includes me in deciding my course of treatment and methods of handling side effects like anemia and fatigue

Sep 20, 2023

Dr.Turner was very helpful.

Aug 10, 2023

5.0 stars

Dr Turner told me of possible down the road treatments when I asked about them.

May 21, 2023

Very helpful

Apr 27, 2023

5.0 stars

Very good

Apr 26, 2023

I understood clearly what she told me

Feb 23, 2023

5.0 stars

I feel very good with this provider & the new medical regimen.

Jan 20, 2023